AFos inhibits phenylephrine-mediated contractile dysfunction by altering phospholamban phosphorylation. - Wikidata - awgldk - TriplyDB

AFos inhibits phenylephrine-mediated contractile dysfunction by altering phospholamban phosphorylation.

AFos inhibits phenylephrine-mediated contractile dysfunction by altering phospholamban phosphorylation.

http://www.wikidata.org/entity/Q33917067

about

The Function of Rho-Associated Kinases ROCK1 and ROCK2 in the Pathogenesis of Cardiovascular Disease Biomimetic Polymers for Cardiac Tissue Engineering.Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling.CD36 protein influences myocardial Ca2+ homeostasis and phospholipid metabolism: conduction anomalies in CD36-deficient mice during fasting.MAP kinase kinase kinase-2 (MEKK2) regulates hypertrophic remodeling of the right ventricle in hypoxia-induced pulmonary hypertension.Lung Vascular Remodeling, Cardiac Hypertrophy, and Inflammatory Cytokines in SHIVnef-Infected Macaques.C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.

P2860

Q26774795-11995198-E9F9-4126-8606-0064C7DA5FE0 Q27301442-F79976DB-84C6-4913-9BE3-AB518864AE74 Q35315318-F45EF210-B233-49BE-BE36-EE52AB8AAB5E Q36385906-B1141419-5A04-4428-B973-190F84F35BE8 Q36528033-80109224-892F-4E65-956A-ADDBA5F76D1D Q47277266-0B29919D-4491-4B18-A07B-87503B6ACCC0 Q47987941-7928F059-1C07-435F-8A60-AC87FBDC1A1E

P2860

AFos inhibits phenylephrine-mediated contractile dysfunction by altering phospholamban phosphorylation.

http://www.wikidata.org/entity/Q33917067

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

AFos inhibits phenylephrine-me ...... phospholamban phosphorylation.

@ast

AFos inhibits phenylephrine-me ...... phospholamban phosphorylation.

@en

type

label

AFos inhibits phenylephrine-me ...... phospholamban phosphorylation.

@ast

AFos inhibits phenylephrine-me ...... phospholamban phosphorylation.

@en

prefLabel

AFos inhibits phenylephrine-me ...... phospholamban phosphorylation.

@ast

AFos inhibits phenylephrine-me ...... phospholamban phosphorylation.

@en

P1433

Q33917067-967FC1CC-20AD-4101-B8E6-047130D265C1

P1476

Q33917067-31A20244-61E7-490A-A7B7-8FADA434BCB8

P2093

Q33917067-50D614F0-AAF6-4D76-A144-AECDE9B64C9D

Q33917067-60192009-95A3-47B1-906E-3CAED9100F6B

Q33917067-87E3596B-26F0-4BC0-AD26-3E88DD221C46

Q33917067-95514CD6-D7BC-402F-97AA-9E0DDFC42DE9

Q33917067-E24C332E-DDE2-49E6-9730-EDE545C81F8D

Q33917067-E5993B92-8C51-4B5E-BF46-CA2D3EAF8D3B

P2860

Q33917067-05A4B692-9A49-4C06-B7D8-88A0046FC4AD

Q33917067-07698389-971C-429D-9253-3966C3CE7F21

Q33917067-16A9D979-6E00-496B-BA0D-25D1331A9B2B

Q33917067-222015A2-F142-4C10-B93F-3A4C992DD26B

Q33917067-2AB9CCB4-C7A5-46FC-A01A-14F2DDC18BBB

Q33917067-3B4AB196-B820-40ED-96B6-A91368C8EF71

Q33917067-3ECD5160-B8C6-4EBA-BFA0-11DFEF4B88B0

Q33917067-50DABCD1-9514-45B8-92EC-F731FF7D772E

Q33917067-524E842F-80A4-4940-9644-A4DB2B8DE404

Q33917067-5B9D8E28-89F7-4E6C-9B34-1D34CDA42C9D

P304

Q33917067-E01EF8EA-AAAC-4033-B365-92FEE0B4E123

P31

Q33917067-A51E3909-A1E1-4767-BA78-0A3E2F264A82

P356

Q33917067-24C027ED-E496-449B-AC7B-6DD8415883E8

P433

Q33917067-B4AAA56F-CF61-421B-93E2-0894697F0BEC

P478

Q33917067-B28F5727-1630-4C32-9971-96D3B6E96B04

P50

Q33917067-4CAB9042-7595-40D9-875D-3737F71B2D84

P577

Q33917067-487349CA-D80D-46B7-9A40-A7DFDB5B830E

P5875

Q33917067-D45069ED-270F-497E-876A-ACAC29D793CE

P698

Q33917067-90D175D0-138D-43BC-A6A8-76B44EA852EA

P921

Q33917067-BE2EA891-45C1-463F-BBFD-B41729C587CA

P932

Q33917067-B773935C-1296-4EEE-9F5C-6C043E7F721A

P356

AJPHEART.00937.2009

P1433

American Journal of Physiology - Heart and Circulatory Physiology

P1476

AFos inhibits phenylephrine-me ...... phospholamban phosphorylation.

@en

P2093

Charles S Vinson

http://www.w3.org/2001/XMLSchema#string

John S Walker

http://www.w3.org/2001/XMLSchema#string

Mark Y Jeong

http://www.w3.org/2001/XMLSchema#string

R Dale Brown

http://www.w3.org/2001/XMLSchema#string

Russell L Moore

http://www.w3.org/2001/XMLSchema#string

Wilson S Colucci

http://www.w3.org/2001/XMLSchema#string

P2860

YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

AP-1 in cell proliferation and survival

AP-1 as a regulator of cell life and death

A dilution immunoassay to measure myosin regulatory light chain phosphorylation.

AFos dissociates cardiac myocyte hypertrophy and expression of the pathological gene program

Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban.

Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity.

A human polymorphism of protein phosphatase-1 inhibitor-1 is associated with attenuated contractile response of cardiomyocytes to beta-adrenergic stimulation.

JunD attenuates phenylephrine-mediated cardiomyocyte hypertrophy by negatively regulating AP-1 transcriptional activity.

P304

H1719-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPHEART.00937.2009

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

298

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42975739

http://www.w3.org/2001/XMLSchema#string

P698

20363890

http://www.w3.org/2001/XMLSchema#string

P921

phosphorylation

P932

2886629

http://www.w3.org/2001/XMLSchema#string